Progress of immune checkpoint inhibitors in treatment of malignant lymphoma
10.3760/cma.j.issn.1009-9921.2019.12.002
- VernacularTitle: 免疫检查点抑制剂在淋巴瘤治疗中的研究进展
- Author:
Qingpei GUAN
1
;
Tingting ZHANG
;
Xianhuo WANG
;
Huilai ZHANG
Author Information
1. Department of Lymphoma, Tianjin Medical University Cancer Hospital, National Clinical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Sino-US Center for Lymphoma Diagnosis and Treatment, Tianjin 300060, China
- Publication Type:Review
- Keywords:
Lymphoma;
Immune checkpoints;
Immunotherapy;
Programned death 1;
Programmed death-ligand 1
- From:
Journal of Leukemia & Lymphoma
2019;28(12):709-712
- CountryChina
- Language:Chinese
-
Abstract:
The immune checkpoint inhibitors (ICI) represented by programmed death 1/programmed death ligand 1 (PD-1/PD-L1) antibody opened a new era of immunotherapy. However, PD-1/PD-L1 inhibitors have not been approved for indications in the field of malignant lymphoma except for classic Hodgkin lymphoma (cHL) and primary mediastinal large B-cell lymphoma. Researchers have actively explored different lymphoma subtypes with single drugs or combined therapy, and achieved certain effect initially. The latest advances of ICI in cHL, B-cell non-Hodgkin lymphoma and T-cell lymphoma and the management of immune-related adverse events are briefly introduced in this paper.
